Skip to main content

REVIEW article

Front. Cardiovasc. Med.
Sec. Hypertension
Volume 11 - 2024 | doi: 10.3389/fcvm.2024.1409212
This article is part of the Research Topic The Newer Paradigms in Hypertension Research and Management View all 8 articles

Malignant Hypertension: Current Challenges, Prevention Strategies, and Future Perspectives

Provisionally accepted
Abate Wondesen Tsige Abate Wondesen Tsige 1*Yehualashet Teshome Wondmkun Yehualashet Teshome Wondmkun 1Siraye Genzeb Ayele Siraye Genzeb Ayele 2
  • 1 Debre Berhan University, Debre Berhan, Ethiopia
  • 2 Addis Ababa University, Addis Ababa, Addis Ababa, Ethiopia

The final, formatted version of the article will be published soon.

    Introduction: Based on the office blood pressure (BP) values, hypertension(HTN) is categorized into three stages: stages 1 (140-159/90-99 mmHg), stages 2 (160-179/100-109 mmHg), and stages 3 (≥180/≥110 mmHg). Malignant hypertension (MHT) is characterized by extreme BP elevations(systolic above 200 mmHg and diastolic above 130 mmHg) and acute microvascular damage affecting various organs, particularly the retina, brain, and kidney.Present medical criteria state that individuals with malignant hypertension (MHT) have extremely high blood pressure (systolic above 200 mmHg and diastolic above 130 mmHg) together with at least three organ dysfunctions (kidney, heart, brain, or microangiopathy).Objectives: Pathogenesis, predisposing variables, therapy, and preventive strategies for MHT were examined in the current review.and efficient treatment because it is the most severe kind of hypertension that affects targetmultiple organs. At the same time, there are a number of alternatives available for treating MHT, the ISH 2020 and ESC/ESH 2018 recommendations suggest using labetalol and nicardipine as the first-line choice, with urapidil and nitroprusside serving as alternative medications. Elevated risk of MHT has been linked to many socio-demographic and genetic factors.

    Keywords: malignant hypertension, Risk factors, complication, Treatment, and Prevention strategies

    Received: 29 Mar 2024; Accepted: 04 Dec 2024.

    Copyright: © 2024 Tsige, Wondmkun and Ayele. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Abate Wondesen Tsige, Debre Berhan University, Debre Berhan, Ethiopia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.